Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

Author(s):

Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.

EP: 1.The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

EP: 2.Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape

EP: 3.First-Line HER2+ Metastatic Breast Cancer Trials in Focus

EP: 4.Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd

EP: 5.Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates

EP: 6.Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer

EP: 7.TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting

Now Viewing

EP: 8.Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

EP: 9.Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses

EP: 10.Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches

EP: 11.Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Video content above is prompted by the following questions:

Patient Case: A 54-year-old woman with HER2+ metastatic breast cancer and brain metastases
- Please describe your initial impressions of this case. How might you have treated this patient in your practice?
Per the NCCN guidelines, what is the preferred treatment approach for this patient/patients with systemic and CNS progression?
In which lines of therapy do the NCCN guidelines recommend using the tucatinib + trastuzumab + capecitabine regimen for patients with brain metastases?
Please discuss the differences between active and stable brain metastases and how these factors influence your treatment decisions.
- At what points during metastatic breast cancer treatment do you typically screen for brain metastases?
- How do you view the role of systemic therapy versus local therapy in the management of brain metastases in HER2-positive mBC?